Clinical trials: Cancer Pain
Cancer Related Pain (Breakthrough Pain)
A Comparative Study of KW-2246
This is a placebo-controlled, double blind, comparative study to evaluate the efficacy and safety of KW-2246 as rescue medication at an optimal dose, which is determined by dose titration in treating breakthrough pain episodes in…
- Trial name
- 2246-004 (NCT01326689)
- Testing
- KW-2246
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Chemotherapy-induced Neutropenia
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3
To assess Duration of Severe Neutropenia (DSN) in treatment Cycle 1 in patients with advanced or metastatic breast cancer, who have failed >/= 1 but < 5 prior lines of chemotherapy; locally advanced or metastatic non small cell…
- Trial name
- Protective-1 (NCT03102606)
- Testing
- Plinabulin, Pegfilgrastim
- Where
- 18 sites in United States, China and 2 more
- Volunteers
- 105 people
- Sponsor
- BeyondSpring Pharmaceuticals Inc.
Neoplasms
A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants
The purpose of this study is to evaluate the conversion rate based on the number of participants achieving pain control and safety within 1 week after switching the opioid (morphine-like medications) analgesics (drug used to…
- Trial name
- NCT01309386
- Testing
- Tapentadol ER, Morphine SR
- Where
- 22 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Janssen Pharmaceutical K.K.
Opioid-Induced Constipation (OIC)
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
The purpose of this study is to evaluate the effect and safety of NKTR-118 treatment of opioid-induced constipation in patients with non-cancer-related pain, including those patients that have inadequate response to laxative…
- Trial name
- NCT01309841
- Testing
- NKTR-118
- Where
- 117 sites in United States, Australia and 2 more
- Volunteers
- 652 people
- Sponsor
- AstraZeneca
Chronic Pain, Cancer Pain
Prometra Post-Approval Study
The Prometra Pump is approved by the FDA for use in the United States. The purpose of this study is to collect long-term safety data on the Prometra Pump.
- Conditions
- Chronic Pain, Cancer Pain, Intractable Pain, Back Pain
- Trial name
- NCT01854229
- Testing
- Prometra Programmable Intrathecal Infusion Pump
- Where
- 26 sites in United States
- Volunteers
- 400 people
- Sponsor
- Flowonix Medical
Breakthrough Pain
Quality of Life Study Breakthrough Cancer Pain Treated in Medical Oncology Services (CAVIDIOM)
In cancer patients, pain is one of the most common symptoms. The range of reported prevalence of pain varies from 33% to 64% including different stages of cancer, during or after anticancer treatment.
- Trial name
- CAVIDIOM (NCT03435120)
- Testing
- No intervention
- Where
- 14 sites in Spain
- Volunteers
- 118 people
- Sponsor
- Angelini Farmacéutica
Bone Metastasis
Bone Pain Score Validation Initiative
Translation and validation of the BOMET-QoL-10 questionnaire in Germany and assessment of its validity and responsiveness.
- Trial name
- ARIE (NCT02293642)
- Where
- Germany
- Volunteers
- 370 people
- Sponsor
- iOMEDICO AG
Cancer
A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to OxyContin in Korean Cancer Patients
Objectives: To prove non-inferiority of Targin compared to Oxycontin in terms of change of pain intensity 1. Primary objective: Change of pain intensity (NRS 0-10) score (average pain over 24 hours obtained each evening) within 4…
- Trial name
- TOP (NCT01313780)
- Testing
- Oxycodone/Naloxone, Oxycodone(single compound)
- Where
- South Korea
- Volunteers
- 128 people
- Sponsor
- Mundipharma Korea Ltd
Pain, Intractable, Pain Cancer
Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain
This is a Phase 3 study to assess the safety and efficacy of a single epidural administration of Resiniferatoxin versus standard of care for the treatment of intractable pain associated with cancer.
- Trial name
- NCT04572776
- Testing
- Resiniferatoxin, Standard of Care
- Sponsor
- Sorrento Therapeutics, Inc.
Pain, Analgesics, Opioid
A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain
The purpose of this study was to characterize the steady-state pharmacokinetic (metabolism and action) profile of OROS hydromorphone HCI (slow release) in patients who required opioid therapy on a daily basis for chronic pain…
- Trial name
- NCT00410878
- Testing
- OROS Hydromorphone HCI (slow release)
- Volunteers
- 22 people
- Sponsor
- Alza Corporation, DE, USA
Pain; Bone Neoplasms; Neoplasm Metastasis
A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.
This single arm study will assess the efficacy and safety of loading doses of intravenous Bondronat in patients with breast cancer and malignant bone disease experiencing moderate to severe bone pain.
- Trial name
- NCT00502736
- Testing
- ibandronate [Bondronat]
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 13 people
- Sponsor
- Hoffmann-La Roche
Bone Pain, Metastatic Bone Tumor
Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain
This is an open label, 2-part early phase study designed to evaluate the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of TLX090-Tx in patients with painful bone metastases.
- Conditions
- Bone Pain, Metastatic Bone Tumor, Bone Metastases in Subjects With Advanced Cancer
- Trial name
- SOLACE (NCT07197645)
- Testing
- 153Sm-DOTMP
- Where
- 6 sites in United States
- Volunteers
- 33 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer
This Phase 2, open-label, multicenter study will evaluate the safety and preliminary efficacy of axelopran in combination with pembrolizumab in patients with PD-L1 positive recurrent or metastatic head and neck squamous cell…
- Trial name
- MORALE-HN01 (NCT07662720)
- Testing
- axelopran, Pembolizumab
- Volunteers
- 18 people
- Sponsor
- Glycyx Therapeutics
Breakthrough Pain, Cancer
Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer
The purpose of the study is to assess the clinical effectiveness of Fentanyl ETHYPHARM when used to relieve breakthrough pain (BTP) in opioid-treated cancer patients.
- Trial name
- ETHYFYL (NCT01842893)
- Testing
- Fentanyl Ethypharm
- Where
- Czechia
- Volunteers
- 91 people
- Sponsor
- Ethypharm
Pain, Neoplasm Metastasis
Safety and Efficacy of Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
This study will evaluate the safety and efficacy of cryoablation therapy combined with radiation therapy for the relief of pain associated with metastatic bone tumors.
- Trial name
- NCT01461252
- Testing
- Cryoablation, Radiation
- Sponsor
- Boston Scientific Corporation
Chronic Pain
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects
The purpose of this study is to evaluate the effectiveness, tolerability, and safety of oxymorphone immediate release (IR) oral liquid as an analgesic in pediatric subjects having severe to moderate chronic pain.
- Trial name
- NCT01206907
- Testing
- oxymorphone IR
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Pain, Cancer
A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients
This study is designed to determine whether KW-2246 is superior to placebo and not inferior to immediate-release morphine for the relief of breakthrough pain in cancer patients.
- Trial name
- NCT00684632
- Testing
- KW-2246 (fentanyl citrate)
- Where
- 20 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Pain, Cancer
Tetrodotoxin Open-label Efficacy and Safety Continuation Study
Different pathophysiologic mechanisms are responsible for the development of chronic pain disorders. Pain pathways are triggered in part by ectopic discharges of voltage-sensitive sodium channels, which are in abundance in both…
- Trial name
- TEC-006OL (NCT00726011)
- Testing
- Tetrodotoxin
- Where
- Canada
- Volunteers
- 113 people
- Sponsor
- Wex Pharmaceuticals Inc.
Pain
A Study to Evaluate the Safety and Effectiveness of Fentanyl-TTS Compared to Weak Opioids in Patients With Moderate to Severe Chronic Cancer Pain Previously Treated With NSAIDS (Non-steroidal Anti-inflammatory Drugs).
To show, using the analgesic WHO scale, that fentanyl-TTS may be directly used for treating moderate to severe cancer pain in patients treated with NSAIDs, acetaminophen, or metamizole (first step drugs) avoiding the second step…
- Trial name
- NCT00576017
- Testing
- Fentanyl-TTS
- Volunteers
- 19 people
- Sponsor
- Janssen-Cilag, S.A.
Malignant Pain, Non-malignant Pain
To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain
This study is aimed to demonstrate equivalence between combinations of lower strength OXN PR tablets (OXN PR LST) and single higher strength OXN PR tablets (OXN PR HST) taken at the same overall daily dose.
- Trial name
- NCT02321397
- Testing
- Oxycodone, Naloxone
- Where
- Germany
- Volunteers
- 155 people
- Sponsor
- Mundipharma Research GmbH & Co KG